menu
    • menu
    [{"orgOrder":0,"company":"reMYND","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ReS3-T","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"reMYND \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"reMYND \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Handl therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Handl therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Handl therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"Handl therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AGT100216","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Augustine Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augustine Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Augustine Therapeutics \/ Eli Lilly"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Augustine Therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            Augustine Therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGT100216

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $18.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Augustine Therapeutics Raises €17 Million in Series A for Neurological Lead Candidate

                            Details : The proceeds from the financing will be used to advance Augustine’s lead candidate, AGT100216, into early-stage clinical trials for the treatment of CMT and CIPN.

                            Product Name : AGT100216

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 26, 2024

                            Lead Product(s) : AGT100216

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $18.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Confo Therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            Confo Therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFTX-1554

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Confo Therapeutics Expands Patent Estate for ConfoBody®-Based GPCR Screening Platform

                            Details : The newly added patent cover Confo’s well-established small molecule screening capabilities, which led to the discovery of CFTX-1554 designed to address peripheral neuropathic pain while avoiding centrally mediated side effects, such as addiction and s...

                            Product Name : CFTX-1554

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 15, 2021

                            Lead Product(s) : CFTX-1554

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            reMYND

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            reMYND

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ReS3-T

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Institute of Neurological Disorders and Stroke

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) Begin Collaboration on Epilepsy Program

                            Details : The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3). ReS3-T acts via a novel proprietary target, Pde6δ, to control neuronal activity.

                            Product Name : ReS3-T

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 11, 2021

                            Lead Product(s) : ReS3-T

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute of Neurological Disorders and Stroke

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Handl therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            Handl therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            UCB Acquires Handl Therapeutics BV

                            Details : Acquisition of Handl Therapeutics BV augments UCB’s existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid technology platform and capabilities.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 11, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Confo Therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            Confo Therapeutics

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFTX-1554

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

                            Details : Confo has applied its proprietary, fragment-based drug discovery and structure-guided drug design technologies to identify CFTX-1554, a novel inhibitor of angiotensin II type 2 receptor, or AT2R, a clinically validated target for the treatment of neuropa...

                            Product Name : CFTX-1554

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 15, 2020

                            Lead Product(s) : CFTX-1554

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth